Novartis STEER Study Success
This is a news story, published by Yahoo Finance, that relates primarily to SMA news.
stocks trading & speculation news
For more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Novartis AG. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest gene therapy innovation news, innovative medicines news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
NovartisTipRanks
•Novartis’ Gene Therapy Shows Promise in Treating SMA
79% Informative
Novartis announced the success of its Phase III STEER study for treating spinal muscular atrophy ( SMA ) Type 2 in children and young adults.
The study demonstrated an increase in motor function, showcasing the therapy’s efficacy and safety compared to a sham control.
VR Score
70
Informative language
65
Neutral language
38
Article tone
formal
Language
English
Language complexity
71
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
6
Source diversity
2
Affiliate links
no affiliate links